Pharma & Healthcare
Global IL-17 Inhibitors for Psoriasis Market Outlook, In‑Depth Analysis & Forecast to 2031
- Oct 21, 25
- ID: 553969
- Pages: 142
- Figures: 131
- Views: 6
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global IL-17 Inhibitors for Psoriasis market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
UCB
Eli Lilly
Novartis
Ortho Dermatologics
LEO Pharma
Kyowa Kirin
Jiangsu Hengrui Pharmaceuticals
Chongqing Genrix Biopharmaceutical
Segment by Type
Bimelizumab
Secukinumab
Ixekizumab
Brodalumab
Vunakizumab
Xeligekimab
Other
Segment by Application
Hospital and Clinic
Pharmacy
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the IL-17 Inhibitors for Psoriasis study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global IL-17 Inhibitors for Psoriasis market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
UCB
Eli Lilly
Novartis
Ortho Dermatologics
LEO Pharma
Kyowa Kirin
Jiangsu Hengrui Pharmaceuticals
Chongqing Genrix Biopharmaceutical
Segment by Type
Bimelizumab
Secukinumab
Ixekizumab
Brodalumab
Vunakizumab
Xeligekimab
Other
Segment by Application
Hospital and Clinic
Pharmacy
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the IL-17 Inhibitors for Psoriasis study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to IL-17 Inhibitors for Psoriasis: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global IL-17 Inhibitors for Psoriasis Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Bimelizumab
1.2.3 Secukinumab
1.2.4 Ixekizumab
1.2.5 Brodalumab
1.2.6 Vunakizumab
1.2.7 Xeligekimab
1.2.8 Other
1.3 Market Segmentation by Application
1.3.1 Global IL-17 Inhibitors for Psoriasis Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global IL-17 Inhibitors for Psoriasis Revenue Estimates and Forecasts 2020-2031
2.2 Global IL-17 Inhibitors for Psoriasis Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global IL-17 Inhibitors for Psoriasis Sales Estimates and Forecasts 2020-2031
2.4 Global IL-17 Inhibitors for Psoriasis Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global IL-17 Inhibitors for Psoriasis Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global IL-17 Inhibitors for Psoriasis Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Bimelizumab Market Size by Manufacturers
3.5.2 Secukinumab Market Size by Manufacturers
3.5.3 Ixekizumab Market Size by Manufacturers
3.5.4 Brodalumab Market Size by Manufacturers
3.5.5 Vunakizumab Market Size by Manufacturers
3.5.6 Xeligekimab Market Size by Manufacturers
3.5.7 Other Market Size by Manufacturers
3.6 Global IL-17 Inhibitors for Psoriasis Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global IL-17 Inhibitors for Psoriasis Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global IL-17 Inhibitors for Psoriasis Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global IL-17 Inhibitors for Psoriasis Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global IL-17 Inhibitors for Psoriasis Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America IL-17 Inhibitors for Psoriasis Sales and Revenue by Type (2020-2031)
6.4 North America IL-17 Inhibitors for Psoriasis Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America IL-17 Inhibitors for Psoriasis Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe IL-17 Inhibitors for Psoriasis Sales and Revenue by Type (2020-2031)
7.4 Europe IL-17 Inhibitors for Psoriasis Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe IL-17 Inhibitors for Psoriasis Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific IL-17 Inhibitors for Psoriasis Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific IL-17 Inhibitors for Psoriasis Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific IL-17 Inhibitors for Psoriasis Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America IL-17 Inhibitors for Psoriasis Sales and Revenue by Type (2020-2031)
9.4 Central and South America IL-17 Inhibitors for Psoriasis Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America IL-17 Inhibitors for Psoriasis Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa IL-17 Inhibitors for Psoriasis Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa IL-17 Inhibitors for Psoriasis Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa IL-17 Inhibitors for Psoriasis Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 UCB
11.1.1 UCB Corporation Information
11.1.2 UCB Business Overview
11.1.3 UCB IL-17 Inhibitors for Psoriasis Product Models, Descriptions and Specifications
11.1.4 UCB IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 UCB IL-17 Inhibitors for Psoriasis Sales by Product in 2024
11.1.6 UCB IL-17 Inhibitors for Psoriasis Sales by Application in 2024
11.1.7 UCB IL-17 Inhibitors for Psoriasis Sales by Geographic Area in 2024
11.1.8 UCB IL-17 Inhibitors for Psoriasis SWOT Analysis
11.1.9 UCB Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Corporation Information
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly IL-17 Inhibitors for Psoriasis Product Models, Descriptions and Specifications
11.2.4 Eli Lilly IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Eli Lilly IL-17 Inhibitors for Psoriasis Sales by Product in 2024
11.2.6 Eli Lilly IL-17 Inhibitors for Psoriasis Sales by Application in 2024
11.2.7 Eli Lilly IL-17 Inhibitors for Psoriasis Sales by Geographic Area in 2024
11.2.8 Eli Lilly IL-17 Inhibitors for Psoriasis SWOT Analysis
11.2.9 Eli Lilly Recent Developments
11.3 Novartis
11.3.1 Novartis Corporation Information
11.3.2 Novartis Business Overview
11.3.3 Novartis IL-17 Inhibitors for Psoriasis Product Models, Descriptions and Specifications
11.3.4 Novartis IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Novartis IL-17 Inhibitors for Psoriasis Sales by Product in 2024
11.3.6 Novartis IL-17 Inhibitors for Psoriasis Sales by Application in 2024
11.3.7 Novartis IL-17 Inhibitors for Psoriasis Sales by Geographic Area in 2024
11.3.8 Novartis IL-17 Inhibitors for Psoriasis SWOT Analysis
11.3.9 Novartis Recent Developments
11.4 Ortho Dermatologics
11.4.1 Ortho Dermatologics Corporation Information
11.4.2 Ortho Dermatologics Business Overview
11.4.3 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product Models, Descriptions and Specifications
11.4.4 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales by Product in 2024
11.4.6 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales by Application in 2024
11.4.7 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales by Geographic Area in 2024
11.4.8 Ortho Dermatologics IL-17 Inhibitors for Psoriasis SWOT Analysis
11.4.9 Ortho Dermatologics Recent Developments
11.5 LEO Pharma
11.5.1 LEO Pharma Corporation Information
11.5.2 LEO Pharma Business Overview
11.5.3 LEO Pharma IL-17 Inhibitors for Psoriasis Product Models, Descriptions and Specifications
11.5.4 LEO Pharma IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 LEO Pharma IL-17 Inhibitors for Psoriasis Sales by Product in 2024
11.5.6 LEO Pharma IL-17 Inhibitors for Psoriasis Sales by Application in 2024
11.5.7 LEO Pharma IL-17 Inhibitors for Psoriasis Sales by Geographic Area in 2024
11.5.8 LEO Pharma IL-17 Inhibitors for Psoriasis SWOT Analysis
11.5.9 LEO Pharma Recent Developments
11.6 Kyowa Kirin
11.6.1 Kyowa Kirin Corporation Information
11.6.2 Kyowa Kirin Business Overview
11.6.3 Kyowa Kirin IL-17 Inhibitors for Psoriasis Product Models, Descriptions and Specifications
11.6.4 Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Kyowa Kirin Recent Developments
11.7 Jiangsu Hengrui Pharmaceuticals
11.7.1 Jiangsu Hengrui Pharmaceuticals Corporation Information
11.7.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.7.3 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product Models, Descriptions and Specifications
11.7.4 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
11.8 Chongqing Genrix Biopharmaceutical
11.8.1 Chongqing Genrix Biopharmaceutical Corporation Information
11.8.2 Chongqing Genrix Biopharmaceutical Business Overview
11.8.3 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product Models, Descriptions and Specifications
11.8.4 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Chongqing Genrix Biopharmaceutical Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 IL-17 Inhibitors for Psoriasis Industry Chain
12.2 IL-17 Inhibitors for Psoriasis Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 IL-17 Inhibitors for Psoriasis Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 IL-17 Inhibitors for Psoriasis Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 IL-17 Inhibitors for Psoriasis Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global IL-17 Inhibitors for Psoriasis Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to IL-17 Inhibitors for Psoriasis: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global IL-17 Inhibitors for Psoriasis Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Bimelizumab
1.2.3 Secukinumab
1.2.4 Ixekizumab
1.2.5 Brodalumab
1.2.6 Vunakizumab
1.2.7 Xeligekimab
1.2.8 Other
1.3 Market Segmentation by Application
1.3.1 Global IL-17 Inhibitors for Psoriasis Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global IL-17 Inhibitors for Psoriasis Revenue Estimates and Forecasts 2020-2031
2.2 Global IL-17 Inhibitors for Psoriasis Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global IL-17 Inhibitors for Psoriasis Sales Estimates and Forecasts 2020-2031
2.4 Global IL-17 Inhibitors for Psoriasis Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global IL-17 Inhibitors for Psoriasis Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global IL-17 Inhibitors for Psoriasis Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Bimelizumab Market Size by Manufacturers
3.5.2 Secukinumab Market Size by Manufacturers
3.5.3 Ixekizumab Market Size by Manufacturers
3.5.4 Brodalumab Market Size by Manufacturers
3.5.5 Vunakizumab Market Size by Manufacturers
3.5.6 Xeligekimab Market Size by Manufacturers
3.5.7 Other Market Size by Manufacturers
3.6 Global IL-17 Inhibitors for Psoriasis Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global IL-17 Inhibitors for Psoriasis Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global IL-17 Inhibitors for Psoriasis Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global IL-17 Inhibitors for Psoriasis Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global IL-17 Inhibitors for Psoriasis Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America IL-17 Inhibitors for Psoriasis Sales and Revenue by Type (2020-2031)
6.4 North America IL-17 Inhibitors for Psoriasis Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America IL-17 Inhibitors for Psoriasis Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe IL-17 Inhibitors for Psoriasis Sales and Revenue by Type (2020-2031)
7.4 Europe IL-17 Inhibitors for Psoriasis Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe IL-17 Inhibitors for Psoriasis Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific IL-17 Inhibitors for Psoriasis Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific IL-17 Inhibitors for Psoriasis Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific IL-17 Inhibitors for Psoriasis Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America IL-17 Inhibitors for Psoriasis Sales and Revenue by Type (2020-2031)
9.4 Central and South America IL-17 Inhibitors for Psoriasis Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America IL-17 Inhibitors for Psoriasis Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa IL-17 Inhibitors for Psoriasis Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa IL-17 Inhibitors for Psoriasis Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa IL-17 Inhibitors for Psoriasis Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 UCB
11.1.1 UCB Corporation Information
11.1.2 UCB Business Overview
11.1.3 UCB IL-17 Inhibitors for Psoriasis Product Models, Descriptions and Specifications
11.1.4 UCB IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 UCB IL-17 Inhibitors for Psoriasis Sales by Product in 2024
11.1.6 UCB IL-17 Inhibitors for Psoriasis Sales by Application in 2024
11.1.7 UCB IL-17 Inhibitors for Psoriasis Sales by Geographic Area in 2024
11.1.8 UCB IL-17 Inhibitors for Psoriasis SWOT Analysis
11.1.9 UCB Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Corporation Information
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly IL-17 Inhibitors for Psoriasis Product Models, Descriptions and Specifications
11.2.4 Eli Lilly IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Eli Lilly IL-17 Inhibitors for Psoriasis Sales by Product in 2024
11.2.6 Eli Lilly IL-17 Inhibitors for Psoriasis Sales by Application in 2024
11.2.7 Eli Lilly IL-17 Inhibitors for Psoriasis Sales by Geographic Area in 2024
11.2.8 Eli Lilly IL-17 Inhibitors for Psoriasis SWOT Analysis
11.2.9 Eli Lilly Recent Developments
11.3 Novartis
11.3.1 Novartis Corporation Information
11.3.2 Novartis Business Overview
11.3.3 Novartis IL-17 Inhibitors for Psoriasis Product Models, Descriptions and Specifications
11.3.4 Novartis IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Novartis IL-17 Inhibitors for Psoriasis Sales by Product in 2024
11.3.6 Novartis IL-17 Inhibitors for Psoriasis Sales by Application in 2024
11.3.7 Novartis IL-17 Inhibitors for Psoriasis Sales by Geographic Area in 2024
11.3.8 Novartis IL-17 Inhibitors for Psoriasis SWOT Analysis
11.3.9 Novartis Recent Developments
11.4 Ortho Dermatologics
11.4.1 Ortho Dermatologics Corporation Information
11.4.2 Ortho Dermatologics Business Overview
11.4.3 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product Models, Descriptions and Specifications
11.4.4 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales by Product in 2024
11.4.6 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales by Application in 2024
11.4.7 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales by Geographic Area in 2024
11.4.8 Ortho Dermatologics IL-17 Inhibitors for Psoriasis SWOT Analysis
11.4.9 Ortho Dermatologics Recent Developments
11.5 LEO Pharma
11.5.1 LEO Pharma Corporation Information
11.5.2 LEO Pharma Business Overview
11.5.3 LEO Pharma IL-17 Inhibitors for Psoriasis Product Models, Descriptions and Specifications
11.5.4 LEO Pharma IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 LEO Pharma IL-17 Inhibitors for Psoriasis Sales by Product in 2024
11.5.6 LEO Pharma IL-17 Inhibitors for Psoriasis Sales by Application in 2024
11.5.7 LEO Pharma IL-17 Inhibitors for Psoriasis Sales by Geographic Area in 2024
11.5.8 LEO Pharma IL-17 Inhibitors for Psoriasis SWOT Analysis
11.5.9 LEO Pharma Recent Developments
11.6 Kyowa Kirin
11.6.1 Kyowa Kirin Corporation Information
11.6.2 Kyowa Kirin Business Overview
11.6.3 Kyowa Kirin IL-17 Inhibitors for Psoriasis Product Models, Descriptions and Specifications
11.6.4 Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Kyowa Kirin Recent Developments
11.7 Jiangsu Hengrui Pharmaceuticals
11.7.1 Jiangsu Hengrui Pharmaceuticals Corporation Information
11.7.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.7.3 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product Models, Descriptions and Specifications
11.7.4 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
11.8 Chongqing Genrix Biopharmaceutical
11.8.1 Chongqing Genrix Biopharmaceutical Corporation Information
11.8.2 Chongqing Genrix Biopharmaceutical Business Overview
11.8.3 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product Models, Descriptions and Specifications
11.8.4 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Chongqing Genrix Biopharmaceutical Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 IL-17 Inhibitors for Psoriasis Industry Chain
12.2 IL-17 Inhibitors for Psoriasis Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 IL-17 Inhibitors for Psoriasis Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 IL-17 Inhibitors for Psoriasis Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 IL-17 Inhibitors for Psoriasis Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global IL-17 Inhibitors for Psoriasis Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global IL-17 Inhibitors for Psoriasis Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global IL-17 Inhibitors for Psoriasis Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global IL-17 Inhibitors for Psoriasis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global IL-17 Inhibitors for Psoriasis Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global IL-17 Inhibitors for Psoriasis Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global IL-17 Inhibitors for Psoriasis Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global IL-17 Inhibitors for Psoriasis Sales by Region (2020-2025) & (K Units)
Table 8. Global IL-17 Inhibitors for Psoriasis Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global IL-17 Inhibitors for Psoriasis Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global IL-17 Inhibitors for Psoriasis Sales Share by Manufacturers (2020-2025)
Table 12. Global IL-17 Inhibitors for Psoriasis Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global IL-17 Inhibitors for Psoriasis by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in IL-17 Inhibitors for Psoriasis as of 2024)
Table 16. Global IL-17 Inhibitors for Psoriasis Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global IL-17 Inhibitors for Psoriasis Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers IL-17 Inhibitors for Psoriasis Manufacturing Base and Headquarters
Table 19. Global IL-17 Inhibitors for Psoriasis Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global IL-17 Inhibitors for Psoriasis Sales by Type (2020-2025) & (K Units)
Table 23. Global IL-17 Inhibitors for Psoriasis Sales by Type (2026-2031) & (K Units)
Table 24. Global IL-17 Inhibitors for Psoriasis Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global IL-17 Inhibitors for Psoriasis Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global IL-17 Inhibitors for Psoriasis ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global IL-17 Inhibitors for Psoriasis Sales by Application (2020-2025) & (K Units)
Table 29. Global IL-17 Inhibitors for Psoriasis Sales by Application (2026-2031) & (K Units)
Table 30. IL-17 Inhibitors for Psoriasis High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global IL-17 Inhibitors for Psoriasis Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global IL-17 Inhibitors for Psoriasis Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global IL-17 Inhibitors for Psoriasis ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America IL-17 Inhibitors for Psoriasis Growth Accelerators and Market Barriers
Table 37. North America IL-17 Inhibitors for Psoriasis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America IL-17 Inhibitors for Psoriasis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe IL-17 Inhibitors for Psoriasis Growth Accelerators and Market Barriers
Table 40. Europe IL-17 Inhibitors for Psoriasis Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe IL-17 Inhibitors for Psoriasis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific IL-17 Inhibitors for Psoriasis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific IL-17 Inhibitors for Psoriasis Growth Accelerators and Market Barriers
Table 45. Southeast Asia IL-17 Inhibitors for Psoriasis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America IL-17 Inhibitors for Psoriasis Investment Opportunities and Key Challenges
Table 47. Central and South America IL-17 Inhibitors for Psoriasis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa IL-17 Inhibitors for Psoriasis Investment Opportunities and Key Challenges
Table 49. Middle East and Africa IL-17 Inhibitors for Psoriasis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. UCB Corporation Information
Table 51. UCB Description and Major Businesses
Table 52. UCB Product Models, Descriptions and Specifications
Table 53. UCB Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. UCB Sales Value Proportion by Product in 2024
Table 55. UCB Sales Value Proportion by Application in 2024
Table 56. UCB Sales Value Proportion by Geographic Area in 2024
Table 57. UCB IL-17 Inhibitors for Psoriasis SWOT Analysis
Table 58. UCB Recent Developments
Table 59. Eli Lilly Corporation Information
Table 60. Eli Lilly Description and Major Businesses
Table 61. Eli Lilly Product Models, Descriptions and Specifications
Table 62. Eli Lilly Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Eli Lilly Sales Value Proportion by Product in 2024
Table 64. Eli Lilly Sales Value Proportion by Application in 2024
Table 65. Eli Lilly Sales Value Proportion by Geographic Area in 2024
Table 66. Eli Lilly IL-17 Inhibitors for Psoriasis SWOT Analysis
Table 67. Eli Lilly Recent Developments
Table 68. Novartis Corporation Information
Table 69. Novartis Description and Major Businesses
Table 70. Novartis Product Models, Descriptions and Specifications
Table 71. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Novartis Sales Value Proportion by Product in 2024
Table 73. Novartis Sales Value Proportion by Application in 2024
Table 74. Novartis Sales Value Proportion by Geographic Area in 2024
Table 75. Novartis IL-17 Inhibitors for Psoriasis SWOT Analysis
Table 76. Novartis Recent Developments
Table 77. Ortho Dermatologics Corporation Information
Table 78. Ortho Dermatologics Description and Major Businesses
Table 79. Ortho Dermatologics Product Models, Descriptions and Specifications
Table 80. Ortho Dermatologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Ortho Dermatologics Sales Value Proportion by Product in 2024
Table 82. Ortho Dermatologics Sales Value Proportion by Application in 2024
Table 83. Ortho Dermatologics Sales Value Proportion by Geographic Area in 2024
Table 84. Ortho Dermatologics IL-17 Inhibitors for Psoriasis SWOT Analysis
Table 85. Ortho Dermatologics Recent Developments
Table 86. LEO Pharma Corporation Information
Table 87. LEO Pharma Description and Major Businesses
Table 88. LEO Pharma Product Models, Descriptions and Specifications
Table 89. LEO Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. LEO Pharma Sales Value Proportion by Product in 2024
Table 91. LEO Pharma Sales Value Proportion by Application in 2024
Table 92. LEO Pharma Sales Value Proportion by Geographic Area in 2024
Table 93. LEO Pharma IL-17 Inhibitors for Psoriasis SWOT Analysis
Table 94. LEO Pharma Recent Developments
Table 95. Kyowa Kirin Corporation Information
Table 96. Kyowa Kirin Description and Major Businesses
Table 97. Kyowa Kirin Product Models, Descriptions and Specifications
Table 98. Kyowa Kirin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Kyowa Kirin Recent Developments
Table 100. Jiangsu Hengrui Pharmaceuticals Corporation Information
Table 101. Jiangsu Hengrui Pharmaceuticals Description and Major Businesses
Table 102. Jiangsu Hengrui Pharmaceuticals Product Models, Descriptions and Specifications
Table 103. Jiangsu Hengrui Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Jiangsu Hengrui Pharmaceuticals Recent Developments
Table 105. Chongqing Genrix Biopharmaceutical Corporation Information
Table 106. Chongqing Genrix Biopharmaceutical Description and Major Businesses
Table 107. Chongqing Genrix Biopharmaceutical Product Models, Descriptions and Specifications
Table 108. Chongqing Genrix Biopharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Chongqing Genrix Biopharmaceutical Recent Developments
Table 110. Key Raw Materials Distribution
Table 111. Raw Materials Key Suppliers
Table 112. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 113. Milestones in Production Technology Evolution
Table 114. Distributors List
Table 115. Market Trends and Market Evolution
Table 116. Market Drivers and Opportunities
Table 117. Market Challenges, Risks, and Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. IL-17 Inhibitors for Psoriasis Product Picture
Figure 2. Global IL-17 Inhibitors for Psoriasis Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Bimelizumab Product Picture
Figure 4. Secukinumab Product Picture
Figure 5. Ixekizumab Product Picture
Figure 6. Brodalumab Product Picture
Figure 7. Vunakizumab Product Picture
Figure 8. Xeligekimab Product Picture
Figure 9. Other Product Picture
Figure 10. Global IL-17 Inhibitors for Psoriasis Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 11. Hospital and Clinic
Figure 12. Pharmacy
Figure 13. Other
Figure 14. IL-17 Inhibitors for Psoriasis Report Years Considered
Figure 15. Global IL-17 Inhibitors for Psoriasis Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 17. Global IL-17 Inhibitors for Psoriasis Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 18. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Region (2020-2031)
Figure 19. Global IL-17 Inhibitors for Psoriasis Sales (2020-2031) & (K Units)
Figure 20. Global IL-17 Inhibitors for Psoriasis Sales (CAGR) by Region (2020-2031) (K Units)
Figure 21. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Region (2020-2031)
Figure 22. Top 5 and Top 10 Manufacturers IL-17 Inhibitors for Psoriasis Sales Volume Market Share in 2024
Figure 23. Global IL-17 Inhibitors for Psoriasis Revenue Market Share Ranking (2024)
Figure 24. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 25. Bimelizumab Revenue Market Share by Manufacturer in 2024
Figure 26. Secukinumab Revenue Market Share by Manufacturer in 2024
Figure 27. Ixekizumab Revenue Market Share by Manufacturer in 2024
Figure 28. Brodalumab Revenue Market Share by Manufacturer in 2024
Figure 29. Vunakizumab Revenue Market Share by Manufacturer in 2024
Figure 30. Xeligekimab Revenue Market Share by Manufacturer in 2024
Figure 31. Other Revenue Market Share by Manufacturer in 2024
Figure 32. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2020-2031)
Figure 33. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2020-2031)
Figure 34. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2020-2031)
Figure 35. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application (2020-2031)
Figure 36. North America IL-17 Inhibitors for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 37. North America IL-17 Inhibitors for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 38. North America Top 5 Manufacturers IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 39. North America IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Type (2020- 2031)
Figure 40. North America IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 41. North America IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 42. North America IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 43. US IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 44. Canada IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 45. Mexico IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 46. Europe IL-17 Inhibitors for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 47. Europe IL-17 Inhibitors for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 48. Europe Top 5 Manufacturers IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 49. Europe IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Type (2020-2031)
Figure 50. Europe IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 51. Europe IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 52. Europe IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 53. Germany IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 54. France IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 55. U.K. IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 56. Italy IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 57. Russia IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 58. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 59. Asia-Pacific IL-17 Inhibitors for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 60. Asia-Pacific Top 8 Manufacturers IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 61. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Type (2020- 2031)
Figure 62. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 63. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 64. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 65. Indonesia IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 66. Japan IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 67. South Korea IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 68. China Taiwan IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 69. India IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 70. Central and South America IL-17 Inhibitors for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 71. Central and South America IL-17 Inhibitors for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 72. Central and South America Top 5 Manufacturers IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 73. Central and South America IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Type (2021-2031)
Figure 74. Central and South America IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 75. Central and South America IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 76. Central and South America IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 77. Brazil IL-17 Inhibitors for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 78. Argentina IL-17 Inhibitors for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 79. Middle East, and Africa IL-17 Inhibitors for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 80. Middle East and Africa IL-17 Inhibitors for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 81. Middle East and Africa Top 5 Manufacturers IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 82. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Type (2021-2031)
Figure 83. South America IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 84. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 85. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 86. GCC Countries IL-17 Inhibitors for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 87. Turkey IL-17 Inhibitors for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 88. Egypt IL-17 Inhibitors for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 89. South Africa IL-17 Inhibitors for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 90. IL-17 Inhibitors for Psoriasis Industry Chain Mapping
Figure 91. Regional IL-17 Inhibitors for Psoriasis Manufacturing Base Distribution (%)
Figure 92. Global IL-17 Inhibitors for Psoriasis Production Market Share by Region (2020-2031)
Figure 93. IL-17 Inhibitors for Psoriasis Production Process
Figure 94. Regional IL-17 Inhibitors for Psoriasis Production Cost Structure
Figure 95. Channels of Distribution (Direct Vs Distribution)
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed
Table 1. Global IL-17 Inhibitors for Psoriasis Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global IL-17 Inhibitors for Psoriasis Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global IL-17 Inhibitors for Psoriasis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global IL-17 Inhibitors for Psoriasis Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global IL-17 Inhibitors for Psoriasis Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global IL-17 Inhibitors for Psoriasis Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global IL-17 Inhibitors for Psoriasis Sales by Region (2020-2025) & (K Units)
Table 8. Global IL-17 Inhibitors for Psoriasis Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global IL-17 Inhibitors for Psoriasis Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global IL-17 Inhibitors for Psoriasis Sales Share by Manufacturers (2020-2025)
Table 12. Global IL-17 Inhibitors for Psoriasis Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global IL-17 Inhibitors for Psoriasis by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in IL-17 Inhibitors for Psoriasis as of 2024)
Table 16. Global IL-17 Inhibitors for Psoriasis Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global IL-17 Inhibitors for Psoriasis Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers IL-17 Inhibitors for Psoriasis Manufacturing Base and Headquarters
Table 19. Global IL-17 Inhibitors for Psoriasis Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global IL-17 Inhibitors for Psoriasis Sales by Type (2020-2025) & (K Units)
Table 23. Global IL-17 Inhibitors for Psoriasis Sales by Type (2026-2031) & (K Units)
Table 24. Global IL-17 Inhibitors for Psoriasis Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global IL-17 Inhibitors for Psoriasis Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global IL-17 Inhibitors for Psoriasis ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global IL-17 Inhibitors for Psoriasis Sales by Application (2020-2025) & (K Units)
Table 29. Global IL-17 Inhibitors for Psoriasis Sales by Application (2026-2031) & (K Units)
Table 30. IL-17 Inhibitors for Psoriasis High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global IL-17 Inhibitors for Psoriasis Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global IL-17 Inhibitors for Psoriasis Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global IL-17 Inhibitors for Psoriasis ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America IL-17 Inhibitors for Psoriasis Growth Accelerators and Market Barriers
Table 37. North America IL-17 Inhibitors for Psoriasis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America IL-17 Inhibitors for Psoriasis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe IL-17 Inhibitors for Psoriasis Growth Accelerators and Market Barriers
Table 40. Europe IL-17 Inhibitors for Psoriasis Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe IL-17 Inhibitors for Psoriasis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific IL-17 Inhibitors for Psoriasis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific IL-17 Inhibitors for Psoriasis Growth Accelerators and Market Barriers
Table 45. Southeast Asia IL-17 Inhibitors for Psoriasis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America IL-17 Inhibitors for Psoriasis Investment Opportunities and Key Challenges
Table 47. Central and South America IL-17 Inhibitors for Psoriasis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa IL-17 Inhibitors for Psoriasis Investment Opportunities and Key Challenges
Table 49. Middle East and Africa IL-17 Inhibitors for Psoriasis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. UCB Corporation Information
Table 51. UCB Description and Major Businesses
Table 52. UCB Product Models, Descriptions and Specifications
Table 53. UCB Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. UCB Sales Value Proportion by Product in 2024
Table 55. UCB Sales Value Proportion by Application in 2024
Table 56. UCB Sales Value Proportion by Geographic Area in 2024
Table 57. UCB IL-17 Inhibitors for Psoriasis SWOT Analysis
Table 58. UCB Recent Developments
Table 59. Eli Lilly Corporation Information
Table 60. Eli Lilly Description and Major Businesses
Table 61. Eli Lilly Product Models, Descriptions and Specifications
Table 62. Eli Lilly Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Eli Lilly Sales Value Proportion by Product in 2024
Table 64. Eli Lilly Sales Value Proportion by Application in 2024
Table 65. Eli Lilly Sales Value Proportion by Geographic Area in 2024
Table 66. Eli Lilly IL-17 Inhibitors for Psoriasis SWOT Analysis
Table 67. Eli Lilly Recent Developments
Table 68. Novartis Corporation Information
Table 69. Novartis Description and Major Businesses
Table 70. Novartis Product Models, Descriptions and Specifications
Table 71. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Novartis Sales Value Proportion by Product in 2024
Table 73. Novartis Sales Value Proportion by Application in 2024
Table 74. Novartis Sales Value Proportion by Geographic Area in 2024
Table 75. Novartis IL-17 Inhibitors for Psoriasis SWOT Analysis
Table 76. Novartis Recent Developments
Table 77. Ortho Dermatologics Corporation Information
Table 78. Ortho Dermatologics Description and Major Businesses
Table 79. Ortho Dermatologics Product Models, Descriptions and Specifications
Table 80. Ortho Dermatologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Ortho Dermatologics Sales Value Proportion by Product in 2024
Table 82. Ortho Dermatologics Sales Value Proportion by Application in 2024
Table 83. Ortho Dermatologics Sales Value Proportion by Geographic Area in 2024
Table 84. Ortho Dermatologics IL-17 Inhibitors for Psoriasis SWOT Analysis
Table 85. Ortho Dermatologics Recent Developments
Table 86. LEO Pharma Corporation Information
Table 87. LEO Pharma Description and Major Businesses
Table 88. LEO Pharma Product Models, Descriptions and Specifications
Table 89. LEO Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. LEO Pharma Sales Value Proportion by Product in 2024
Table 91. LEO Pharma Sales Value Proportion by Application in 2024
Table 92. LEO Pharma Sales Value Proportion by Geographic Area in 2024
Table 93. LEO Pharma IL-17 Inhibitors for Psoriasis SWOT Analysis
Table 94. LEO Pharma Recent Developments
Table 95. Kyowa Kirin Corporation Information
Table 96. Kyowa Kirin Description and Major Businesses
Table 97. Kyowa Kirin Product Models, Descriptions and Specifications
Table 98. Kyowa Kirin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Kyowa Kirin Recent Developments
Table 100. Jiangsu Hengrui Pharmaceuticals Corporation Information
Table 101. Jiangsu Hengrui Pharmaceuticals Description and Major Businesses
Table 102. Jiangsu Hengrui Pharmaceuticals Product Models, Descriptions and Specifications
Table 103. Jiangsu Hengrui Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Jiangsu Hengrui Pharmaceuticals Recent Developments
Table 105. Chongqing Genrix Biopharmaceutical Corporation Information
Table 106. Chongqing Genrix Biopharmaceutical Description and Major Businesses
Table 107. Chongqing Genrix Biopharmaceutical Product Models, Descriptions and Specifications
Table 108. Chongqing Genrix Biopharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Chongqing Genrix Biopharmaceutical Recent Developments
Table 110. Key Raw Materials Distribution
Table 111. Raw Materials Key Suppliers
Table 112. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 113. Milestones in Production Technology Evolution
Table 114. Distributors List
Table 115. Market Trends and Market Evolution
Table 116. Market Drivers and Opportunities
Table 117. Market Challenges, Risks, and Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. IL-17 Inhibitors for Psoriasis Product Picture
Figure 2. Global IL-17 Inhibitors for Psoriasis Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Bimelizumab Product Picture
Figure 4. Secukinumab Product Picture
Figure 5. Ixekizumab Product Picture
Figure 6. Brodalumab Product Picture
Figure 7. Vunakizumab Product Picture
Figure 8. Xeligekimab Product Picture
Figure 9. Other Product Picture
Figure 10. Global IL-17 Inhibitors for Psoriasis Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 11. Hospital and Clinic
Figure 12. Pharmacy
Figure 13. Other
Figure 14. IL-17 Inhibitors for Psoriasis Report Years Considered
Figure 15. Global IL-17 Inhibitors for Psoriasis Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 17. Global IL-17 Inhibitors for Psoriasis Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 18. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Region (2020-2031)
Figure 19. Global IL-17 Inhibitors for Psoriasis Sales (2020-2031) & (K Units)
Figure 20. Global IL-17 Inhibitors for Psoriasis Sales (CAGR) by Region (2020-2031) (K Units)
Figure 21. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Region (2020-2031)
Figure 22. Top 5 and Top 10 Manufacturers IL-17 Inhibitors for Psoriasis Sales Volume Market Share in 2024
Figure 23. Global IL-17 Inhibitors for Psoriasis Revenue Market Share Ranking (2024)
Figure 24. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 25. Bimelizumab Revenue Market Share by Manufacturer in 2024
Figure 26. Secukinumab Revenue Market Share by Manufacturer in 2024
Figure 27. Ixekizumab Revenue Market Share by Manufacturer in 2024
Figure 28. Brodalumab Revenue Market Share by Manufacturer in 2024
Figure 29. Vunakizumab Revenue Market Share by Manufacturer in 2024
Figure 30. Xeligekimab Revenue Market Share by Manufacturer in 2024
Figure 31. Other Revenue Market Share by Manufacturer in 2024
Figure 32. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2020-2031)
Figure 33. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2020-2031)
Figure 34. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2020-2031)
Figure 35. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application (2020-2031)
Figure 36. North America IL-17 Inhibitors for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 37. North America IL-17 Inhibitors for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 38. North America Top 5 Manufacturers IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 39. North America IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Type (2020- 2031)
Figure 40. North America IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 41. North America IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 42. North America IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 43. US IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 44. Canada IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 45. Mexico IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 46. Europe IL-17 Inhibitors for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 47. Europe IL-17 Inhibitors for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 48. Europe Top 5 Manufacturers IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 49. Europe IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Type (2020-2031)
Figure 50. Europe IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 51. Europe IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 52. Europe IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 53. Germany IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 54. France IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 55. U.K. IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 56. Italy IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 57. Russia IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 58. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 59. Asia-Pacific IL-17 Inhibitors for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 60. Asia-Pacific Top 8 Manufacturers IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 61. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Type (2020- 2031)
Figure 62. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 63. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 64. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 65. Indonesia IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 66. Japan IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 67. South Korea IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 68. China Taiwan IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 69. India IL-17 Inhibitors for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 70. Central and South America IL-17 Inhibitors for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 71. Central and South America IL-17 Inhibitors for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 72. Central and South America Top 5 Manufacturers IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 73. Central and South America IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Type (2021-2031)
Figure 74. Central and South America IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 75. Central and South America IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 76. Central and South America IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 77. Brazil IL-17 Inhibitors for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 78. Argentina IL-17 Inhibitors for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 79. Middle East, and Africa IL-17 Inhibitors for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 80. Middle East and Africa IL-17 Inhibitors for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 81. Middle East and Africa Top 5 Manufacturers IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 82. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Type (2021-2031)
Figure 83. South America IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 84. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 85. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 86. GCC Countries IL-17 Inhibitors for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 87. Turkey IL-17 Inhibitors for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 88. Egypt IL-17 Inhibitors for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 89. South Africa IL-17 Inhibitors for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 90. IL-17 Inhibitors for Psoriasis Industry Chain Mapping
Figure 91. Regional IL-17 Inhibitors for Psoriasis Manufacturing Base Distribution (%)
Figure 92. Global IL-17 Inhibitors for Psoriasis Production Market Share by Region (2020-2031)
Figure 93. IL-17 Inhibitors for Psoriasis Production Process
Figure 94. Regional IL-17 Inhibitors for Psoriasis Production Cost Structure
Figure 95. Channels of Distribution (Direct Vs Distribution)
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Oral Antianginal Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Polyester BCF Yarns Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Glass Mat Reinforced Thermoplastics (GMT) for Automotive Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232